<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006030</url>
  </required_header>
  <id_info>
    <org_study_id>POLARIS2013-003</org_study_id>
    <nct_id>NCT02006030</nct_id>
  </id_info>
  <brief_title>Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <acronym>TACE</acronym>
  <official_title>Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polaris Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polaris Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from&#xD;
      microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been&#xD;
      used to treat patients that have cancers that require arginine. In this study, the&#xD;
      investigators will evaluate the response rate, as determined by the revised International&#xD;
      Working Group recommendations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2014</start_date>
  <completion_date type="Actual">November 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine time to tumor progression (TTP)</measure>
    <time_frame>2 years estimated - course of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rates</measure>
    <time_frame>2 years estimated - course of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ADI-PEG 20 + TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADI-PEG 20 plus concurrent transarterial chemoembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transarterial chemoembolization (TACE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>transarterial chemoembolization alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADI-PEG 20</intervention_name>
    <arm_group_label>ADI-PEG 20 + TACE</arm_group_label>
    <other_name>arginine deiminase formulated with polyethylene glycol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transarterial chemoembolization</intervention_name>
    <arm_group_label>ADI-PEG 20 + TACE</arm_group_label>
    <arm_group_label>Transarterial chemoembolization (TACE)</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of HCC confirmed clinically or histologically or cytologically. A clinical&#xD;
             diagnosis of HCC, using the 2010 Guideline of the American Association for the Study&#xD;
             of Liver Diseases requires the presence of hepatic tumor(s) with image findings (e.g.&#xD;
             sonography, CT or MRI) compatible with HCC, and no evidence of other gastrointestinal&#xD;
             tumors (Bruix [2011] - Guideline, 2010).&#xD;
&#xD;
          2. Solitary hepatic tumor &lt;8 cm in diameter or multifocal disease as evidenced by CT or&#xD;
             MRI scan. Tumor volume ≥50% of liver organ or infiltrating HCC should be excluded.&#xD;
&#xD;
          3. Not a candidate for surgical resection or ablation of the tumor.&#xD;
&#xD;
          4. The target lesion must not have been treated previously with local therapy, including&#xD;
             TACE. Prior local therapy (radiofrequency ablation, percutaneous ethanol injection,&#xD;
             cryoablation, or surgery) to nontarget lesions is acceptable.&#xD;
&#xD;
          5. The subject must have received no more than 2 TACE (n≤ 2) or the previous TACE was&#xD;
             performed longer than 2 months before enrollment.&#xD;
&#xD;
          6. Local therapy must have been completed at least 4 weeks before baseline scan.&#xD;
&#xD;
          7. Measurable disease using mRECIST criteria (Appendix A) and RECIST1.1 (Appendix B)&#xD;
             criteria. At least 1 measurable lesion must be present.&#xD;
&#xD;
          8. Barcelona Clinic Liver Cancer (BCLC) staging classification B (intermediate stage)&#xD;
             (Appendix C).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. 1. Candidate for potential curative therapies (i.e., resection or transplantation).&#xD;
&#xD;
          2. Prior allograft transplantation including liver transplantation.&#xD;
&#xD;
          3. Significant cardiac disease (New York Heart Association Class III or IV; Appendix F).&#xD;
&#xD;
          4. Serious infection requiring treatment with systemically administered antibiotics.&#xD;
&#xD;
          5. Pregnancy or lactation.&#xD;
&#xD;
          6. Expected non-compliance.&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure (New York Heart Association Class III&#xD;
             or IV), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness or social&#xD;
             situations that would limit compliance with study requirements.&#xD;
&#xD;
          8. Subjects who have had any anticancer treatment within 2 weeks prior to week 1 visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pei-Jer Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital Taipei, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMUH</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TP-VGH</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CGMH-LK</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>November 27, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <disposition_first_submitted>August 30, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>August 30, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 4, 2018</disposition_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable Hepatocellular Carcinoma</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>ADI</keyword>
  <keyword>ADI-PEG 20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

